To screen ETFs by asset class, performance, yield and more, check out the
View PPHMstockofcentury's Comments
Bristol-Myers Squibb Vs. Roche In The Brain Cancer Race
Peter, thanks for shining some light on GBM... certainly a high-unmet need and additional treatment is needed.
It seems that much of the immuno-therapy talk as of late is missing a critical requirement that is needed to improve overall response rates... and that is the targeting of "Phosphatidylserine" which globally targets the entire spectrum that all others such as PD-1, PD-L1, ITL-2, CTLA-4..etc which only target a small portion of this spectrum and is representative on all solid tumors, GBM, Lung Cancer, Breast Cancer, Melanoma..etc ..etc
The Key Opinion Leaders and MOA of Bavituximab is explained in detail below... and is a "requirement" for immunotherapy to achieve a maximum immune response.
Jan 2, 2014. 12:45 PM
Link to Comment
More on BMY by PPHMstockofcentury
Xignite quote data
© 2015 Seeking Alpha